Concepedia

Kathryn Keenan

KK

Statistics

Publications

3

Citations

325

H-Index

3

Active since

2018

Affiliations

GlaxoSmithKline (United States)(Current)

Kathryn Keenan is an author at GlaxoSmithKline (United States) specializing in cancer pharmacology, oncology, and pharmacology.

Publications per year

2018–2021

3

Publications

3

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill et al. · Nature Cancer · 2021 · 280 citations · Full text

Medicine, Oncology, Pharmacology +8

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers

Anastasia Wyce, Jeanne J. Matteo, Shawn W. Foley et al. · Oncogenesis · 2018 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17

A Chemical Acetylation-Based Mass Spectrometry Platform for Histone Methylation Profiling

Francesca Zappacosta, Craig D. Wagner, Anthony Della Pietra et al. · Molecular & Cellular Proteomics · 2021 · 10 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

1–3 of 3